Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
ConclusionMOA switching is associated with higher treatment persistence and lower healthcare costs than TNFi cycling. Reimbursement policies that require patients to cycle TNFi before switching MOA may result in suboptimal outcomes for both patients and payers.FundingSanofi and Regeneron Pharmaceuticals.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Abatacept | Actemra | Arthritis | Databases & Libraries | Drugs & Pharmacology | Enbrel | Healthcare Costs | Humira | Medicare | Orencia | Remicade | Rheumatoid Arthritis | Rheumatology | Study